TLSI Zgłoszenia SEC - TriSalus Life Sciences, Inc.- Raport roczny, oświadczenie o pełnomocnictwie, Prospekt

Podstawowe statystyki

CIK

1826667

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TriSalus Life Sciences, Inc.

SEC Filings (Chronological Order)

Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.

May 14, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 TRISALUS LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organiz
May 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 TRISALUS LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organiz
May 12, 2026	EX-19.1	TRISALUS LIFE SCIENCES, INC. INSIDER TRADING POLICY Adopted by the Board of Directors: August 10, 2023 Effective: August 10, 2023 Amended and Restated: March 26, 2026 EXHIBIT 19.1 TRISALUS LIFE SCIENCES, INC. INSIDER TRADING POLICY Adopted by the Board of Directors: August 10, 2023 Effective: August 10, 2023 Amended and Restated: March 26, 2026 Policy Principles •Employees, directors, officers and designated consultants (each a “Covered Person,” and collectively, “Covered Persons”) of TriSalus Life Sciences, Inc. and its subsidiaries (together, the “Company”) (
May 12, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
May 12, 2026	EX-10.1	FOURTH AMENDMENT TO CREDIT AGREEMENT EXHIBIT 10.1 FOURTH AMENDMENT TO CREDIT AGREEMENT This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of March 26, 2026 by and among TRISALUS OPERATING LIFE SCIENCES, INC., a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC., a Delaware corporation (the “Parent”), the Lenders party hereto (the “Lenders”) and ORBIMED ROYALTY & CREDIT OPPORTUNIT
May 12, 2026	EX-99.1	TriSalus Life Sciences Reports First Quarter 2026 Results Commercial and Clinical Progress for Facilitating Long-Term Growth Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader mar TriSalus Life Sciences Reports First Quarter 2026 Results Commercial and Clinical Progress for Facilitating Long-Term Growth Generated first quarter revenue of $8.
April 29, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 TRISALUS LIFE SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ
April 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 TRISALUS LIFE SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi
April 7, 2026	EX-99.1	TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer WESTMINSTER, Colo. — April 7, 2026 — TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment o
March 31, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
March 31, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39813 TriSalus Life S
March 31, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
March 10, 2026	S-8	As filed with the Securities and Exchange Commission on March 10, 2026 As filed with the Securities and Exchange Commission on March 10, 2026 Registration No.
March 10, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 TriSalus Life Sciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan Common Stock, $0.0001 par value Other 3,331,683
March 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 TRISALUS LIFE SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi
March 5, 2026	EX-4.5	DESCRIPTION OF OUR SECURITIES EXHIBIT 4.5 DESCRIPTION OF OUR SECURITIES Explanatory Note TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), was originally known as MedTech Acquisition Corporation (“MTAC”), a special purpose acquisition company. On August 10, 2023, MTAC consummated a business combination with privately held TriSalus Life Sciences, Inc. pursuant to that certain
March 5, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-398
March 5, 2026	EX-99.1	TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53% , respectiv TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance Reports $13.
February 26, 2026	424B5	9,756,100 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-291509 PROSPECTUS SUPPLEMENT (To prospectus dated December 4, 2025) 9,756,100 Shares of Common Stock TriSalus Life Sciences, Inc. We are offering 9,756,100 shares of our common stock, par value $0.0001 per share (“Common Stock”), in this offering. Our Common Stock is listed on The Nasdaq Global Market under the symbol “TLSI.” On February 18, 20
February 20, 2026	EX-1.1	9,756,100 Shares of Common Stock of TRISALUS LIFE SCIENCES, INC. UNDERWRITING AGREEMENT Exhibit 1.1 9,756,100 Shares of Common Stock of TRISALUS LIFE SCIENCES, INC. UNDERWRITING AGREEMENT February 19, 2026 Lake Street Capital Markets, LLC As Representative of the several Underwriters named on Schedule A hereto 121 South 8th Street, Suite 1000 Minneapolis, Minnesota 55402 Ladies and Gentlemen: 1. Introductory. TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), propo
February 20, 2026	424B5	9,756,100 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-291509 PRELIMINARY PROSPECTUS SUPPLEMENT (To prospectus dated December 4, 2025) 9,756,100 Shares of Common Stock TriSalus Life Sciences, Inc. We are offering 9,756,100 shares of our common stock, par value $0.0001 per share (“Common Stock”), in this offering. Our Common Stock is listed on The Nasdaq Global Market under the symbol “TLSI.” On Feb
February 20, 2026	EX-99.2	TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering Exhibit 99.2 TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering WESTMINSTER, Colo.—(BUSINESS WIRE)— February 20, 2026 — TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, tod
February 20, 2026	EX-99.1	TriSalus Life Sciences Proposes Public Offering Exhibit 99.1 TriSalus Life Sciences Proposes Public Offering WESTMINSTER, Colo.—(BUSINESS WIRE)— February 19, 2026 — TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced that it inten
February 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 TRISALUS LIFE S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or or
February 19, 2026	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 19, 2026 Filed pursuant to Rule 424(b)(5) Registration No. 333-291509 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit
February 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2026 TRISALUS LIFE SC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org
February 9, 2026	EX-99.1	TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors WESTMINSTER, Colo.
January 12, 2026	EX-99.1	TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exce TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance Fourth quarter 2025 revenue of approximately $13.
January 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 TRISALUS LIFE SC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org
December 2, 2025	CORRESP	TRISALUS LIFE SCIENCES, INC. 6272 W. 91st. Ave. Westminster, Colorado 80031 TRISALUS LIFE SCIENCES, INC. 6272 W. 91st. Ave. Westminster, Colorado 80031 December 2, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Nick O’Leary Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 File No. 333-291509 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Secu
November 13, 2025	EX-4.3	TRISALUS LIFE SCIENCES, INC., DATED AS OF , 20__ SENIOR DEBT SECURITIES TABLE OF CONTENTS Exhibit 4.3 TRISALUS LIFE SCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.1 Designation and Terms of Securities 3 Section 2.2 Form of Securities and Trustee’s Certificat
November 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 TRISALUS LIFE S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or or
November 13, 2025	S-3	As filed with the U.S. Securities and Exchange Commission on November 13, 2025 As filed with the U.S. Securities and Exchange Commission on November 13, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorporation or orga
November 13, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) TriSalus Life Sciences, Inc. (Exact Name of Registrant as Specified in its Charter Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) TriSalus Life Sciences, Inc.
November 13, 2025	EX-4.4	TRISALUS LIFE SCIENCES, INC., DATED AS OF , 20__ SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Exhibit 4.4 TRISALUS LIFE SCIENCES, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 3 Section 2.01 Designation and Terms of Securities 3 Section 2.02 Form of Securities and Trustee’s Ce
November 13, 2025	EX-99.1	TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enable TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance TriSalus Reports $11.
November 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
October 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 TRISALUS LIFE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or o
August 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 TRISALUS LIFE SCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or orga
August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 TRISALUS LIFE SCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or orga
August 12, 2025	EX-99.1	TriSalus Life Sciences Second Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers $11.2M in revenues resulting in 52% growth year-over-year and 22% growth quarter-over-quarter Broadened PEDD portfolio with launch of TriNav FLX de TriSalus Life Sciences Second Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers $11.
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001
August 12, 2025	EX-10.2	Sign-on Bonus Agreement, by and between the Company and David Patience, dated May 27, 2025 Exhibit 10.2 SIGN-ON BONUS AGREEMENT THIS SIGN-ON BONUS AGREEMENT (“Agreement”) is entered into on the 1st day of July, 2025 (the “Effective Date”), by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Mr. David Patience (the “Employee”). NOW, THEREFORE, in consideration of the mutual promises made below, the parties agree as follows: 1.Sign-On Bonus. The Compan
August 12, 2025	EX-10.3	Consulting Agreement, by and between the Company and David Patience, dated June 2, 2025 Exhibit 10.3 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into effective as of Monday, June 2, 2025 (the “Effective Date”) by and betwe
August 12, 2025	EX-10.1	Executive Employment Agreement, by and between the Company and David Patience, dated May 27, 2025 Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of July 1, 202
July 25, 2025	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) TRISALUS LIFE SCIENCES, INC. (Name of Subject Compa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Series A Convertible Preferred Stock (Title of Class of Securities) Not Applicable (CUSIP Number of Class of Securitie
July 24, 2025	EX-3.1	Certificate of Amendment to Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF TRISALUS LIFE SCIENCES, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock (the “Amendment”) is dated as of July 24, 2
July 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 TRISALUS LIFE SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi
July 24, 2025	EX-99.1	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock EXHIBIT 99.1 TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock WESTMINSTER, CO — July 24, 2025 — TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, announced the completion of its previously disclosed exchange offer and consent solicita
July 15, 2025	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TRISALUS LIFE SCIENCES, INC. (Name of Subject Compa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Series A Convertible Preferred Stock (Title of Class of Securities) Not Applicable (CUSIP Number of Class of Securitie
July 11, 2025	S-4/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on July 11, 2025 Registration No. 333-288250 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of i
June 23, 2025	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Pers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Series A Convertible Preferred Stock (Title of Class of Securities) Not Applicable (CUSIP Number of Class of Securities) Mary Szela Chie
June 23, 2025	EX-99.4	Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Shares of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59
June 23, 2025	S-4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on [ ], 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorporation or organization
June 23, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form TO (Form Type) TriSalus Life Sciences, Inc.
June 23, 2025	EX-99.1	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure EXHIBIT 99.1 TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure WESTMINSTER, CO — June 23, 2025 — TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics
June 23, 2025	EX-99.1	Form of Letter of Transmittal and Consent. Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Shares of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JULY 23, 2025, OR SUCH LAT
June 23, 2025	EX-99.3	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Shares of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTE
June 23, 2025	EX-99.2	Form of Notice of Guaranteed Delivery. Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF SHARES OF PREFERRED STOCK OF TRISALUS LIFE SCIENCES, INC. Pursuant to the Prospectus/Offer to Exchange dated July 23, 2025 Instructions for Use Unless defined herein, terms used in this Notice of Guaranteed Delivery shall have definitions set forth in the Prospectus/Offer to Exchange dated July 23, 2025. This Notice of Guaranteed Delivery, or one subst
June 23, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi
June 23, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) TriSalus Life Sciences, Inc.
June 16, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi
June 6, 2025	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 June 6, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Nicholas O’Leary Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 May 30, 2025 File No. 333-287696 Ladies and Gentlemen:
June 6, 2025	LETTER	LETTER June 6, 2025 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, CO 80031 Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 Filed May 30, 2025 File No. 333-287696 Dear Mary Szela: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accel
May 30, 2025	EX-10.1	AGREEMENT AND RELEASE EXHIBIT 10.1 AGREEMENT AND RELEASE This Agreement and Release ("Agreement") is made by and between TriSalus Life Sciences, Inc. (the "Company"), and James Young (the "Executive") (collectively referred to herein as the "Parties" and each a "Party"). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below). WHEREAS, th
May 30, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
May 30, 2025	EX-4.4	Registration Rights Agreement, dated May 2, 2025, by and among TriSalus Life Sciences, Inc. and the person party thereto. Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT   THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 2, 2025, is entered into by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms
May 30, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) TriSalus Life Sciences, Inc.
May 30, 2025	S-3	As filed with the U.S. Securities and Exchange Commission on May 30, 2025 As filed with the U.S. Securities and Exchange Commission on May 30, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorporation or organizat
May 30, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organiz
May 30, 2025	EX-99.1	TriSalus Life Sciences Announces Chief Financial Officer Transition with Appointment of David B. Patience David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current EXHIBIT 99.1 TriSalus Life Sciences Announces Chief Financial Officer Transition with Appointment of David B. Patience David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period Denver, CO – May
May 28, 2025	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 May 28, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Conlon Danberg Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 April 28, 2025 File No. 333-286797 Ladies and Gentlemen:
May 15, 2025	EX-99.1	TriSalus Life Sciences First Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial foo TriSalus Life Sciences First Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET DENVER – May 15, 2025 - TriSalus Life Sciences, Inc.
May 15, 2025	EX-10.2	Amendment No. 1 to Strategic Collaboration Agreement, dated March 2, 2021, by and between Surefire Medical Inc. d/b/a TriSalus Life Sciences and the University of Texas M.D. Anderson Cancer Center EXHIBIT 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT No. 1 TO STRATEGIC COLLABORATION AGREEMENT This Amendment No. 1 to the March 2, 2021 Strategic Collaboration Agreement ( "Amendment 1") is effective as of February 25, 2025 ("Amendment Effective Date"
May 15, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organiz
May 15, 2025	EX-10.1	Second Amendment to Credit Agreement by and between TriSalus Operating Life Sciences, Inc., TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. EXHIBIT 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of April 30, 2025 by and among TRISALUS OPERATING LIFE SCIENCES, INC., a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC., a Delaware corporation (the “Parent”), the Lenders party hereto (the “Lenders”) and ORBIMED ROYALTY & CREDIT OPPORTUNIT
May 15, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
May 5, 2025	LETTER	LETTER May 5, 2025 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 Filed April 28, 2025 File No. 333-286797 Dear Mary Szela: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests fo
April 30, 2025	EX-99.1	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Excha Exhibit 99.1 TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Sup
April 30, 2025	EX-99.1	TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Excha Exhibit 99.1 TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Sup
April 30, 2025	EX-10.3	Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. Exhibit 10.3 Execution Version TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the persons listed on Schedule A hereto (collectively, the “Preferred Stock Holders,” and each a “Preferred Stock Holder”). WITNESSETH: WHEREAS, as of the date hereof,
April 30, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 30, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ
April 30, 2025	EX-10.1	Securities Purchase Agreement, dated April 30, 2025, by and among TriSalus Life Sciences, Inc. and the persons party thereto. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliver
April 30, 2025	EX-10.2	Form of Registration Rights Agreement. Exhibit 10.2 Final Form REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April [●], 2025, is entered into by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capi
April 30, 2025	LETTER	LETTER April 30, 2025 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, CO 80031 Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 Filed April 25, 2025 File No. 333-286779 Dear Mary Szela: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for a
April 30, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39813 TRISALUS LIFE S
April 30, 2025	EX-10.2	Form of Registration Rights Agreement Exhibit 10.2 Final Form REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April [●], 2025, is entered into by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capi
April 30, 2025	EX-10.1	Securities Purchase Agreement, dated April 30, 2025, by and among TriSalus Life Sciences, Inc. and the persons party thereto. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliver
April 30, 2025	EX-10.3	Tender and Support Agreement, dated April 30, 2025, by and among TriSalus Life Sciences, Inc. and the persons party thereto. Exhibit 10.3 Execution Version TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the persons listed on Schedule A hereto (collectively, the “Preferred Stock Holders,” and each a “Preferred Stock Holder”). WITNESSETH: WHEREAS, as of the date hereof,
April 30, 2025	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 April 30, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Margaret Sawicki Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 Filed April 25, 2025 File No. 333-286779 Ladies and G
April 30, 2025	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 TRISALUS LIFE SCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ
April 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) TriSalus Life Sciences, Inc.
April 28, 2025	EX-4.3	Securities Purchase Agreement, dated December 12, 2024, between TriSalus Life Sciences, Inc. and the Purchasers listed on Exhibit A thereto. Exhibit 4.3 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of December 12, 2024, between TriSalus Life Sciences, Inc., a Delaware corporation, with offices at 6272 West 91ST Avenue, Westminster, CO 80031 (the “Company”) and each of those persons and entities, severally and not jointly, whose names are set forth on the Schedule of Pu
April 28, 2025	S-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 As filed with the U.S. Securities and Exchange Commission on April 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 85-3009869 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (State or other jurisdiction of incorporation or organiz
April 25, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) TriSalus Life Sciences, Inc.
April 25, 2025	S-8	As filed with the Securities and Exchange Commission on April 25, 2025 As filed with the Securities and Exchange Commission on April 25, 2025 Registration No.
April 25, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TriSalus Life Sciences, Inc.
April 25, 2025	S-3	As filed with the U.S. Securities and Exchange Commission on April 25, 2025 As filed with the U.S. Securities and Exchange Commission on April 25, 2025 Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 85-3009869 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (State or other jurisdiction of incorporation or org
April 23, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ
April 17, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ
April 15, 2025	EX-10.26	First Amendment to Credit Agreement and Registration Rights Agreement by and between TriSalus Operating Life Sciences, Inc., TriSalus Life Sciences, Inc., OrbiMed Royalty & Credit Opportunities IV, LP., and OrbiMed Royalty & Credit Opportunities IV Offshore, LP. EXHIBIT 10.26 FIRST AMENDMENT TO CREDIT AGREEMENT AND REGISTRATION RIGHTS AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of March 20, 2025 by and among TRISALUS OPERATING LIFE SCIENCES, INC., a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC., a Delaware corporation (the “Parent”), the Lenders p
April 15, 2025	EX-10.31	Amendment No. 2 to Amended and Restated Executive Employment Agreement, dated January 6, 2025, by and between TriSalus Life Sciences, Inc. and Richard Marshak. EXHIBIT 10.31 AMENDMENT NO. 2 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 2 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of Monday, January 6, 2025 (the “Amendment Effective Date”) by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Richard Marshak, an individual (the “Execut
April 15, 2025	EX-10.22	Amended and Restated Executive Employment Agreement, Dated January 6, 2025, by and between TriSalus Life Sciences, Inc. and Jodi Devlin EXHIBIT 10.22 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of Monday, January 6, 2
April 15, 2025	EX-21.1	List of Subsidiaries EXHIBIT 21.1 List of Subsidiaries of TriSalus Life Sciences, Inc. Name Jurisdiction of Incorporation or Organization TriSalus Operating Life Sciences, Inc. Delaware
April 15, 2025	EX-4.10	Warrant Certificate, dated February 18, 2025, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, L.P. EXHIBIT 4.10 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATIO
April 15, 2025	EX-4.11	Warrant Certificate, dated February 18, 2025, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV Offshore, L.P. EXHIBIT 4.11 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATIO
April 15, 2025	EX-10.30	Amendment No. 1 to Amended and Restated Executive Employment Agreement, dated January 24, 2024, by and between TriSalus Life Sciences, Inc. and Richard Marshak. EXHIBIT 10.30 AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of Wednesday, January 24, 2024 (the “Amendment Effective Date”) by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Richard Marshak, an individual (the “Ex
April 15, 2025	EX-10.13	Amended and Restated Non-Employee Director Compensation Policy. EXHIBIT 10.13 TriSalus Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to TriSalus Life Sciences, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy
April 15, 2025	EX-19.1	TriSalus Life Sciences, Inc. Insider Trading Policy AMENDED AND RESTATED TRISALUS LIFE SCIENCES, INC. INSIDER TRADING POLICY Adopted by the Board of Directors: January 24, 2024 Effective: January 24, 2024 Policy Principles •Employees, directors, officers and designated consultants (each a “Covered Person,” and collectively, “Covered Persons”) of TriSalus Life Sciences, Inc. and its subsidiaries (together, the “Company”) (or any other person or enti
April 15, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-398
March 28, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR o For Period Ended: December 31, 2023 o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR o For Period Ended: December 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition
March 27, 2025	EX-99.1	TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update •Revenues of $8.
March 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ
February 25, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or or
February 19, 2025	8-K	Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or or
February 3, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org
February 3, 2025	EX-99.1	TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed DENVER, Colo.
January 31, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org
January 23, 2025	EX-99.1	TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call •4Q Sales of approximately $8.3 million represent approximately 44% growth versus 2023 •Full year 2024 Sales of approximately $29.4 mil TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call •4Q Sales of approximately $8.
January 23, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org
January 8, 2025	EX-10.1	by and between the Company and James Young, Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of January 6,
January 8, 2025	EX-10.2	Amended and Restated Executive Employment Agreement, by and between the Company and Sean Murphy, dated January 6, 2025. Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Ag
January 8, 2025	EX-99.1	TriSalus Announces Leadership Changes James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Operations Exhibit 99.1 TriSalus Announces Leadership Changes James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Operations DENVER – January 8, 2025 - TriSalus Life Sciences, Inc., (Nasdaq: TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery tech
January 8, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi
December 4, 2024	SC 13G	TLSI / TriSalus Life Sciences, Inc. / PALLOTTA JAMES J - SC 13G Passive Investment SC 13G 1 tm2430131d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRISALUS LIFE SCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 89680M101 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of this Statement)
November 14, 2024	EX-99.1	TriSalus Life Sciences Condensed Consolidated Statement of Operations (unaudited, in thousands) Exhibit 99.1 TriSalus Reports Q3 2024 Financial Results and Provides Business Update · Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year · Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 · Launched TriNav® LV In
November 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Com
November 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
November 6, 2024	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 November 6, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Robert Augustin Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 File No. 333-282882 Ladies and Gentlemen: TriSalus L
November 6, 2024	POS AM	As filed with the U.S. Securities and Exchange Commission on November 6, 2024. As filed with the U.S. Securities and Exchange Commission on November 6, 2024. Registration No. 333-276070 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j
November 1, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Comm
October 29, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) TriSalus Life Sciences, Inc.
October 29, 2024	EX-4.11	Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc, and OrbiMed Royalty & Credit Opportunities IV Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	EX-4.10	Substitute Warrant Certificate, August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	POS AM	As filed with the U.S. Securities and Exchange Commission on October 29, 2024. As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j
October 29, 2024	EX-4.11	Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV Offshore, LP. Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	EX-4.11	Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV Offshore, LP. Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	EX-4.11	Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV Offshore, LP. Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	EX-4.10	Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	POS AM	As filed with the U.S. Securities and Exchange Commission on October 29, 2024 As filed with the U.S. Securities and Exchange Commission on October 29, 2024 Registration No. 333-280197 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 85-3009869 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (S
October 29, 2024	EX-4.10	Substitute Warrant Certificate, August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	S-3	As filed with the U.S. Securities and Exchange Commission on October 29, 2024. S-3 1 tm2426916d4s3.htm FORM S-3 As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inco
October 29, 2024	EX-4.10	Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc, and OrbiMed Royalty & Credit Opportunities IV, LP. Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS
October 29, 2024	POS AM	As filed with the U.S. Securities and Exchange Commission on October 29, 2024. As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333-276070 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j
October 21, 2024	SC 13G	TLSI / TriSalus Life Sciences, Inc. / Lombard International Assurance S.a. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TriSalus Life Sciences Inc. (Name of Issuer) Common stock (Title of Class of Securities) 89680M101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f
August 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi
August 15, 2024	EX-99.1	TriSalus Life Sciences Condensed Consolidated Statement of Operations (unaudited, in thousands) Exhibit 99.1 TriSalus Reports Q2 2024 Financial Results and Business Update · Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods · Reported gross margin of 88% in Q2 2024 and 86% for six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods · Announces
August 15, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
August 15, 2024	424B3	130,805 Shares of Common Stock Issuable Upon Exercise of Warrant Filed pursuant to Rule 424(b)(3) Registration No. 333-280197 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated June 14, 2024) 130,805 Shares of Common Stock Issuable Upon Exercise of Warrant This prospectus supplement supplements the prospectus dated June 14, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280197). This prospectus supplement is bei
August 15, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
August 14, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001
August 14, 2024	424B3	130,805 Shares of Common Stock Issuable Upon Exercise of Warrant Filed pursuant to Rule 424(b)(3) Registration No. 333-280197 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated June 14, 2024) 130,805 Shares of Common Stock Issuable Upon Exercise of Warrant This prospectus supplement supplements the prospectus dated June 14, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280197). This prospectus supplement is bei
August 14, 2024	EX-4.7	Exhibit 4.7 EXHIBIT 4.7 DESCRIPTION OF OUR SECURITIES Explanatory Note TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), was originally known as MedTech Acquisition Corporation (“MTAC”), a special purpose acquisition company. On August 10, 2023, MTAC consummated a business combination with privately held TriSalus Life Sciences, Inc. pursuant to that certain
August 14, 2024	EX-10.2	Second Amendment to Lease of Space dated July 17, 2024, by and between TriSalus Life Sciences, Inc. and BPAZ Holdings 14, LLC. SECOND AMENDMENT TO LEASE OF SPACE 7/17/2024 This Second Amendment to Lease of Space (“Amendment”) is made this day of July, 2024, between BPAZ HOLDINGS 14, LLC, a Delaware limited liability company (“Landlord”), and TRISALUS LIFE SCIENCES, INC.
August 14, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
July 19, 2024	ARS	ARS ANNUAL REPORT 2023 Dear Fellow Shareholders, As we look back on our first year as a public company, I am pleased to report that 2023 was a significant year of advancement for TriSalus Life Sciences.
July 19, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
July 1, 2024	424B3	130,805 Shares of Common Stock Issuable Upon Exercise of Warrant Filed pursuant to Rule 424(b)(3) Registration No. 333-280197 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated June 14, 2024) 130,805 Shares of Common Stock Issuable Upon Exercise of Warrant This prospectus supplement supplements the prospectus dated June 14, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280197). This prospectus supplement is bei
July 1, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
July 1, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 TRISALUS LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi
July 1, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
July 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 TRISALUS LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi
July 1, 2024	EX-99.1	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation Exhibit 99.1 TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation WESTMINSTER, CO - (BUSINESS WIRE) – July 1, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the clo
July 1, 2024	EX-99.1	TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation Exhibit 99.1 TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation WESTMINSTER, CO - (BUSINESS WIRE) – July 1, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the clo
June 27, 2024	EX-99.1	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants Exhibit 99.1 TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants WESTMINSTER, CO - (BUSINESS WIRE) – June 26, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreat
June 27, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TRISALUS LIFE SCIEN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss
June 27, 2024	EX-99.1	TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants Exhibit 99.1 TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants WESTMINSTER, CO - (BUSINESS WIRE) – June 26, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreat
June 27, 2024	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss
June 27, 2024	EX-10.1	Amendment No. 1 to Warrant Agreement, dated June 26, 2024, by and between the Company and Continental Stock Transfer & Trust Company. Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This Amendment (this “Amendment”) is made as of June 26, 2024, by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”) (f/k/a MedTech Acquisition Corporation (“MTAC”)), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that cert
June 27, 2024	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TRISALUS LIFE SCIENCES, INC. (Name of Subject Compa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Warrants to Acquire Shares of Common Stock (Title of Class of Securities) 89680M119 (CUSIP Number of Class of Securiti
June 27, 2024	EX-10.1	Amendment No. 1 to Warrant Agreement, dated June 26, 2024, by and between the Company and Continental Stock Transfer & Trust Company. Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This Amendment (this “Amendment”) is made as of June 26, 2024, by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”) (f/k/a MedTech Acquisition Corporation (“MTAC”)), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that cert
June 26, 2024	424B3	TRISALUS LIFE SCIENCES, INC. Offer to Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE 424B3 1 tm2415050-3424b3.htm 424B3 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-279691 PROSPECTUS/OFFER TO EXCHANGE TRISALUS LIFE SCIENCES, INC. Offer to Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND WITHDRAWAL RIGHTS WILL EX
June 20, 2024	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 June 20, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Conlon Danberg Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-1 File No. 333-280197 Ladies and Gentlemen: TriSalus Life
June 18, 2024	LETTER	LETTER United States securities and exchange commission logo June 18, 2024 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc.
June 14, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) TriSalus Life Sciences, Inc.
June 14, 2024	S-1	As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorpo
May 24, 2024	S-4	As filed with the U.S. Securities and Exchange Commission on May 24, 2024 Table of Contents As filed with the U.S. Securities and Exchange Commission on May 24, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorpor
May 24, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
May 24, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) TriSalus Life Sciences, Inc.
May 24, 2024	EX-99.1	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants Exhibit 99.1 TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants DENVER - (BUSINESS WIRE) - May 24, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced
May 24, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TRISALUS LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi
May 24, 2024	EX-10.29	Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. Exhibit 10.29 FORM OF TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of [·], 2024, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the persons listed on Schedule A hereto (collectively, the “Warrant Holders,” and each a “Warrant Holder”). WITNESSETH: WHEREAS, as of the date hereof, each Warrant Holder is the ben
May 24, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
May 24, 2024	EX-99.4	Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M.
May 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TRISALUS LIFE SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi
May 24, 2024	EX-99.3	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN S
May 24, 2024	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Pers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Warrants to Acquire Shares of Common Stock (Title of Class of Securities) 89680M119 (CUSIP Number of Class of Securities) Mary Szela Chi
May 24, 2024	EX-99.2	Form of Notice of Guaranteed Delivery. Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF TRISALUS LIFE SCIENCES, INC. Pursuant to the Prospectus/Offer to Exchange dated May 24, 2024 Instructions for Use Unless defined herein, terms used in this Notice of Guaranteed Delivery shall have definitions set forth in the Prospectus/Offer to Exchange dated May 24, 2024. This Notice of Guaranteed Delivery, or one substantially in the for
May 24, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Schedule TO (Form Type) TriSalus Life Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Transaction Valuation Transaction value(1) Fee rate Amount of filing fee(2) Fees to Be Paid $ 12,77 Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Form Type) TriSalus Life Sciences, Inc.
May 24, 2024	EX-99.1	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants Exhibit 99.1 TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants DENVER - (BUSINESS WIRE) - May 24, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced
May 24, 2024	EX-99.1	Form of Letter of Transmittal Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JUNE 25, 2024, OR SUCH LATER T
May 24, 2024	EX-10.28	Form of Dealer Manager and Solicitation Agent Agreement. Exhibit 10.28 TRISALUS LIFE SCIENCES, INC. Dealer Manager and Solicitation Agent Agreement May 24, 2024 Oppenheimer & Co. Inc, as Dealer Manager 85 Broad Street, 23rd Floor New York, NY 10004 Ladies and Gentlemen: TriSalus Life Sciences, Inc., a Delaware corporation (the “Company” or “we”), plans to make an offer (such offer as described in the Prospectus (as defined below), together with the rela
May 15, 2024	EX-4.4	Registration Rights Agreement, dated April 30, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 30, 2024, by and between TriSalus Life Sciences, Inc.
May 15, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
May 15, 2024	EX-4.5	Warrant Certificate, dated April 30, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT C
May 15, 2024	EX-99.1	TriSalus Reports Q1 2024 Financial Results and Business Update Exhibit 99.1 TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24 · Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives · Announced the appointment of Liselotte Hyveled to the Board of Directors · Full year sales growth ex
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00
May 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi
May 15, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
May 15, 2024	EX-10.1	Credit Agreement, dated April 30, 2024, by and between TriSalus Operating Life Sciences, Inc., TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
May 7, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 TRISALUS LIFE SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissio
May 7, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
May 7, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
April 30, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 TRISALUS LIFE SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commis
April 30, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which
April 30, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem
April 30, 2024	EX-99.1	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives Exhibit 99.1 TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives · $25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds · Capital from the transaction is expected to support execution of strategic expansion and f
April 17, 2024	POS AM	As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Registration No. 333-276070 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or oth
April 17, 2024	POS AM	As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or oth
April 16, 2024	EX-16.1	Letter from KPMG LLP to the SEC, dated April 15, 2024. Exhibit 16.1 April 15, 2024 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for TriSalus Life Sciences, Inc. (the Company) and, under the date of April 11, 2024, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2023 and 2022. On April 12, 2024, we were dismissed. W
April 16, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATE SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss
April 11, 2024	EX-97.1	TriSalus Life Sciences, Inc. Incentive Compensation Recoupment Policy TriSalus Life Sciences, Inc. Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recovera
April 11, 2024	EX-10.19	Executive Employment Agreement, Dated August 28, 2023, by and between TriSalus Life Sciences, Inc. and Jodi Devlin AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of Wednesday, January 24, 2024 (the “Amendment Effective Date”) by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Richard Marshak, an individual (the “Executive”) (the
April 11, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-398
April 11, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TriSalus Life Sciences, Inc.
April 11, 2024	EX-4.1	Description of Capital Stock Exhibit 4.1 Description of Securities Explanatory Note TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), was originally known as MedTech Acquisition Corporation (“MTAC”), a special purpose acquisition company. On August 10, 2023, MTAC consummated a business combination with privately held TriSalus Life Sciences, Inc. pursuant to that certain Agr
April 11, 2024	S-8	As filed with the Securities and Exchange Commission on April 11, 2024 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No.
April 2, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe
April 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss
April 1, 2024	EX-99.1	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update Exhibit 99.1 TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update · Reported revenues of $5.7 million in 4Q23, up 77% over prior year · Full year revenues of $18.5 million, up 49% over prior year · Gross Margin of 90% in 4Q23 and 86% for full year · CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code · Real-world data published on TriNa
March 12, 2024	8-K	Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commis
January 25, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Comm
January 25, 2024	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock Up to 5,933,333 Warrants to Purchase Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated December 26, 2023) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated December 26, 2023 (the “Prospectus”),
January 25, 2024	424B3	5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated December 26, 2023) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated December 26, 2023 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and s
January 5, 2024	EX-99.1	1 TriSalus Life Sciences January 2024 Exhibit 99.1 1 TriSalus Life Sciences January 2024 2 Disclaimer Certain statements in this presentation may constitute “forward looking statements” within the meaning of applicable United S tat es federal securities laws. Forward looking statements include, but are not limited to, statements regarding TriSalus’s expectations, hopes, beliefs, intentions or strategies regarding the future including,
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 TRISALUS LIFE SCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi
December 26, 2023	424B3	5,859,375 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS 5,859,375 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholder identified in this prospectus (the “Selling Securityholder”), or its permitted transferees, of up to 5,859,375 shares of our common stock, $0.0001 par value per share (“Common Sto
December 26, 2023	424B3	Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of an aggregate of up to 13,215,112 shares of our common stock, $0.0001 par value per share (
December 21, 2023	LETTER	LETTER United States securities and exchange commission logo December 21, 2023 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc.
December 21, 2023	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 December 21, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Juan Grana Re:          TriSalus Life Sciences, Inc. Registration Statement on Form S-1 File No. 333-276070 Ladies and Gentlemen: TriSalus Life Sciences, Inc. (t
December 21, 2023	CORRESP	TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 December 21, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Juan Grana, Abby Adams Re: TriSalus Life Sciences, Inc. Amendment No. 3 to Registration Statement on Form S-1 File No. 333-274292 Ladies and Gentlemen: TriSalus
December 15, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-1/A (Form Type) TriSalus Life Sciences, Inc.
December 15, 2023	S-1/A	As filed with the U.S. Securities and Exchange Commission on December 14, 2023. Table of Contents As filed with the U.S. Securities and Exchange Commission on December 14, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict
December 15, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) TriSalus Life Sciences, Inc.
December 15, 2023	S-1	As filed with the U.S. Securities and Exchange Commission on December 15, 2023. Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or o
December 14, 2023	CORRESP	Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: +1 858 550 6000 f: +1 858 550-6420 cooley.com Carlos Ramirez T: +1 858 550 6157 [email protected] December 14, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.C. 20549 Attention: Nicholas O’Leary Abby Adams Re: TriSalus Life Sciences, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed October 19, 2023 File No. 333-274292
November 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 TRISALUS LIFE S UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 TRISALUS LIFE SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Com
November 14, 2023	EX-99.1	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior y Exhibit 99.1 TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demo
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
November 6, 2023	LETTER	LETTER United States securities and exchange commission logo November 4, 2023 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc.
October 19, 2023	S-1/A	As filed with the U.S. Securities and Exchange Commission on October 18, 2023. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 18, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti
October 19, 2023	EX-10.14	Executive Employment Agreement, Dated August 28, 2023, by and between TriSalus Life Sciences, Inc. and Jodi Devlin   Exhibit 10.14   CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [**], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.   EXECUTIVE EMPLOYMENT AGREEMENT   THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of August 28, 2023 (the “Effective Da
October 18, 2023	CORRESP	Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117 t: +1 858 550 6000 f: +1 858 550-6420 cooley.com Carlos Ramirez T: +1 858 550 6157 [email protected] October 18, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, NE Washington, D.C. 20549 Attention: Nicholas O’Leary Abby Adams Re: TriSalus Life Sciences, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed September 1, 2023 File No. 333-274292 Ladies and Gentlemen: O
October 16, 2023	S-8	As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No.
October 16, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TriSalus Life Sciences, Inc.
October 3, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi
October 3, 2023	EX-99.1	STANDBY EQUITY PURCHASE AGREEMENT Exhibit 99.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of October 2, 2023 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and TRISALUS LIFE SCIENCES, INC., a company incorporated under the laws of the State of Delaware (the “Company”). WHEREAS, the parties desire that, upon the terms and
September 28, 2023	LETTER	LETTER United States securities and exchange commission logo September 27, 2023 Mary Szela Chief Executive Officer TriSalus Life Sciences, Inc.

TLSI / TriSalus Life Sciences, Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

Podstawowe statystyki

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?